TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11046206
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (4 puffs, 15-20 min before intubation)
Study: 11046206
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg, 3 min before intubation)
Study: 8375519
Drug: Intramuscular hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hCG (10,000 IU)
Study: 8375519
Drug: Intravenous hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hCG (500 IU)
Study: 21901320
Drug: Scopolamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.5 mg)
Study: 3018822
Drug: Methscopolamine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methscopolamine (0.75 mg)
Study: 22999808
Drug: Ipratropium bromide/salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium bromide/salbutamol sulfate (500 μg/2.5 mg) combination
Study: 18294310
Drug: Oral alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alitretinoin 10 mg once daily for up to 24 weeks
Study: 12637478
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 5 days
Study: 12637478
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 3 days
Study: 8611382
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Study: 8611382
Drug: Epirubicin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (70 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Study: 1416333
Drug: Pressurized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized saline canister (220 mL saline at 8 psi)
Study: 1416333
Drug: Syringe irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe irrigation (250 mL saline)
Study: 4074604
Drug: Reproterol 1
Normalized name: reproterol
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol 1 mg
Study: 4074604
Drug: Reproterol 8
Normalized name: reproterol
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol 8 mg
Study: 4074604
Drug: Reproterol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol (various doses)
Study: 12492903
Drug: 0.0625% P‐113
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% P‐113 gel
Study: 12492903
Drug: 0.125% P‐113
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% P‐113 gel
Study: 12492903
Drug: 0.375% P‐113
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% P‐113 gel
Study: 12492903
Drug: P‐113 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐113 treatment groups
Study: 1632542
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with epinephrine (5 micrograms/mL)
Study: 1632542
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with epinephrine (5 micrograms/mL)
Study: 6092287
Drug: Activated charcoal,
Normalized name: activated charcoal, sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal, 50 g given within 5 min of sotalol hydrochloride (160 mg)
Study: 6092287
Drug: Activated charcoal,
Normalized name: activated charcoal, sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal, repeated doses of 50 g followed by 12.5 g at 6 h intervals
Study: 30882914
Drug: 400 or
Normalized name: Nico-400 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 or 800 mg UDCA on day 1, followed by 200 mg UDCA twice daily for 2 weeks
Study: 26875065
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection (IA group)
Study: 26875065
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection (SA group)
Study: 26875065
Drug: Combined IA
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IA and subacromial injections (IA+SA group)
Study: 24390400
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of balanced salt solution (sham injection)
Study: 22112807
Drug: Once-daily (OD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (OD) hydrocortisone dual-release tablet
Study: 20715787
Drug: Three novel
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three novel nonsteroidal glucocorticoid receptor agonists applied at low dose in ethanol solution.
Study: 17697555
Drug: GEMOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMOX regimen (gemcitabine of fixed-dose rate infusion plus oxaliplatin)
Study: 16913264
Drug: Fexofenadine, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine, 180 mg
Study: 2270767
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg fluconazole (oral)
Study: 2270767
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg miconazole (intravaginal)
Study: 17458505
Drug: AZD2171 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2171 at 2.5 mg
Study: 17458505
Drug: AZD2171 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2171 at 20 mg
Study: 17458505
Drug: AZD2171 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2171 at 30 mg
Study: 17458505
Drug: AZD2171 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2171 (various doses)
Study: 15138906
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ropivacaine plus 0.1 mg morphine
Study: 15138906
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg bupivacaine plus 0.1 mg morphine
Study: 12011536
Drug: Piperacillin/tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 4.5 g q6h
Study: 12011536
Drug: Piperacillin/tazobactam 3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam 3.375 g q4h
Study: 26545513
Drug: Traditional Treatment
Normalized name: Midol Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Treatment
Study: 23870217
Drug: Surgicel (oxidized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgicel (oxidized cellulose patch)
Study: 15192621
Drug: High-dose levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose levothyroxine (12.0 microg/kg per day)
Study: 9333592
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 4,000 mg
Study: 9333592
Drug: Magnesium glutamate
Normalized name: magnesium glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium glutamate 2 x 1,000 mg intravenously
Study: 9333592
Drug: Magnesium injection
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium injection
Study: 24722235
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with prednisone and metronidazole (D‐CT, n=10)
Study: 3538446
Drug: Oral trimeprazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimeprazine, droperidol and methadone (TDM)
Study: 3538446
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative medication (unsedated group)
Study: 26852375
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention program (PIP) with 12 weekly group sessions
Study: 31170361
Drug: Intermittent Intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent Intensive Insulin Therapy (IIT)
Study: 19960983
Drug: Metformin (Control)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (Control)
Study: 21596190
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine S(+) 0.050 mg/kg
Study: 21596190
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine S(+) 0.125 mg/kg
Study: 21596190
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine S(+) 0.250 mg/kg
Study: 19389820
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) with insulin glargine and lispro
Study: 11255387
Drug: Ibutilide (0.003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (0.003 mg/kg), infused intravenously for 10 minutes.
Study: 9572724
Drug: traditional self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional self‐administered questionnaire
Study: 8186337
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg each morning, placebo at bedtime)
Study: 8186337
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg each morning and at bedtime)
Study: 2896139
Drug: Delayed-release mesalazine
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release mesalazine
Study: 28985228
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (N = 148)
Study: 23427212
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (manual administration)
Study: 22352122
Drug: Early titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early titration (E) with irbesartan/hydrochlorothiazide 150/12.5 mg for 2 weeks, then up-titrated to 300/25 mg at weeks 2 and 6
Study: 22352122
Drug: Late titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late titration (L) with irbesartan/hydrochlorothiazide 150/12.5 mg for 6 weeks, then up-titrated to 300/25 mg at week 6
Study: 14765987
Drug: l-thyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-thyroxine treatment regimen
Study: 11083889
Drug: Ciprofloxacin (800‐1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (800‐1200 mg/day)
Study: 11083889
Drug: Imipenem (2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (2‐4 g/day)
Study: 9068468
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (250 mg b.i.d.)
Study: 9068468
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin and Placebo
Study: 2658581
Drug: Ciprofloxacin treatment
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin treatment
Study: 2947734
Drug: Thiethylperazine (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiethylperazine (6.5 mg p.o. every 8 h for 5 days)
Study: 2947734
Drug: Thiethylperazine (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiethylperazine (6.5 mg p.o. every 8 h for 5 days) plus amitriptyline (25 mg p.o. every 8 h for 5 days)
Study: 29705442
Drug: Cranberry capsule
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsule
Study: 24509962
Drug: Sample group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sample group (received a demonstration on how to apply the medication using a product sample)
Study: 12575974
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg verapamil
Study: 9819291
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) at high dose (800 micrograms twice daily)
Study: 9819291
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) at high dose (800 micrograms twice daily)
Study: 7641720
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol (Group II)
Study: 7641720
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol supplemented with nitrous oxide (Group III)
Study: 2475699
Drug: Falipamil 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falipamil 100 mg
Study: 2475699
Drug: Falipamil 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falipamil 200 mg
Study: 1093666
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment (Adriamycin to 5-fluorouracil and cyclophosphamide)
Study: 31174929
Drug: Mindful Awareness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful Awareness in Body‐oriented Therapy (MABT)
Study: 26579797
Drug: Low-sodium wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium wheat bread rich in potassium, GABA, and ACEI peptides (LSB+G)
Study: 24280478
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy (60-min sessions, twice a week for a total of ten sessions)
Study: 24280478
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no music therapy)
Study: 21787474
Drug: Xuebijing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing treatment group (n=39, received bundle treatment + Xuebijing treatment)
Study: 21787474
Drug: Routine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine group (n=25, received routine bundle treatment)
Study: 19420392
Drug: School-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based intervention promoting physical activity and healthy eating; details on dosage and duration not specified
Study: 17014519
Drug: Threshold levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold levels recommended by NKF for parathyroid hormone
Study: 10694140
Drug: Low Volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Volume Taper (LVT)
Study: 10694140
Drug: Moderate Volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Volume Taper (MVT)
Study: 10694140
Drug: Taper LICT
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper LICT
Study: 10694140
Drug: Taper HIIT
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper HIIT
Study: 26451734
Drug: Umeclidinium (UMEC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium (UMEC; 62.5 g and 125 g) added to Fluticasone Propionate/Salmeterol (FP/SAL; 250/50 g)
Study: 26451734
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) added to Fluticasone Propionate/Salmeterol (FP/SAL; 250/50 g)
Study: 24378514
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (LPV/r) monotherapy
Study: 20438516
Drug: Conventional, lactate-buffered,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, lactate-buffered, acidic solution (solution D)
Study: 20438516
Drug: Novel, bicarbonate/lactate-buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel, bicarbonate/lactate-buffered neutral solution (solution P)
Study: 10575158
Drug: Adapalene cream
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene cream and gel
Study: 10575158
Drug: Tretinoin creams
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin creams and gels
Study: 8951962
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (1.5 micrograms/kg per spray)
Study: 6310983
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN) plus enteral nutrition
Study: 24559194
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP), mean dose/month 70.3 mg eq. (109.6 mg), median duration of exposure 204 days.
Study: 21173515
Drug: Bucolome combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucolome combination therapy (BC) - bucolome 300 mg/day
Study: 21173515
Drug: Warfarin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin monotherapy (WM)
Study: 15741469
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral social skills training (combined treatment)
Study: 9704181
Drug: Dermofilm (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermofilm (topical preparation)
Study: 7818622
Drug: Acadesine high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acadesine high-dose infusion
Study: 7818622
Drug: Acadesine low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acadesine low-dose infusion
Study: 2698947
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg twice a day for 2 weeks; 40 mg twice a day for 6 weeks)
Study: 31796521
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal
Study: 24596005
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate and 2 mg dienogest
Study: 24596005
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate and 10 mg medroxyprogesterone acetate
Study: 12100094
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rizatriptan plus 25 mg rofecoxib
Study: 7553242
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray with benzalkonium chloride
Study: 10522506
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray without benzalkonium chloride
Study: 7008367
Drug: Silymarin treatment
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin treatment
Study: 31701699
Drug: γ-linolenic acid
Normalized name: γ-linolenic acid
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-linolenic acid (GLA) 320 mg/day
Study: 31701699
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) 600 mg/day
Study: 25748566
Drug: Nebulized pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized pentoxifylline (20 mg/kg every 6 hours for 10 days)
Study: 22321931
Drug: FICB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FICB with ropivacaine 0.2%, 1 ml/kg, max. 30 ml
Study: 22321931
Drug: FICB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FICB with 0.9% normal saline 1 ml/kg, max. 30 ml
Study: 19390463
Drug: Intravaginal estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal estriol (1 mg) and progesterone (30 mg) suppositories
Study: 2383027
Drug: Intralesional sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional sustained release interferon alfa‐2b (10 million IU per injection) - 3 injections
Study: 2383027
Drug: Intralesional sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional sustained release interferon alfa‐2b (10 million IU per injection) - 1 injection
Study: 31163231
Drug: FMX101 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMX101 4% topical minocycline foam
Study: 28160190
Drug: CKD-712 160
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-712 160 µg/kg
Study: 28160190
Drug: CKD-712 320
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-712 320 µg/kg
Study: 28160190
Drug: CKD-712 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-712 (20 to 240 µg/kg)
Study: 22842478
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cyclophosphamide
Study: 20732868
Drug: Relaxin (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxin (four doses)
Study: 16690006
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose venlafaxine (75 mg/d)
Study: 16690006
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose venlafaxine (up to 375 mg/d)
Study: 16690006
Drug: Both low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both low and high doses of venlafaxine
Study: 16225720
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with midazolam 0.1 mg kg(‐1) (Group PM)
Study: 31863040
Drug: Recommendation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendation of root canal treatment for White patients (86.21%)
Study: 28862883
Drug: VR-CHOP (R-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR-CHOP (R-CHOP + bortezomib 1.3 mg/m2 on days 1 and 4)
Study: 24444988
Drug: 0.5 mg/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/hr of ketamine and 2 mg/kg/hr of propofol